Core Viewpoint - The company is planning to issue shares to acquire 100% equity of Zhongji Jiangsu Clean Energy Co., Ltd. from China Technology Import and Export Group Co., Ltd. and simultaneously raise supporting funds for this transaction [2] Group 1: Transaction Overview - The transaction involves the acquisition of Zhongji Jiangsu Clean Energy Co., Ltd. and is classified as a major asset restructuring [2] - The self-inspection period for related parties regarding stock trading is set from November 16, 2024, to September 3, 2025 [3] Group 2: Related Parties and Self-Inspection - The self-inspection scope includes the company, its directors, supervisors, senior management, the counterparty, and other related parties who may have insider information [4] - During the self-inspection period, no legal entities within the insider information scope engaged in stock trading [5] Group 3: Individual Trading Activities - Two individuals within the insider information scope conducted stock trading during the self-inspection period, with declarations stating their actions were based on personal investment decisions and not related to the transaction [5][6] - Both individuals provided commitments to refrain from trading the company's stock until the transaction is completed or terminated [6][7] Group 4: Conclusions and Opinions - The company concludes that the trading activities of the insider information holders did not utilize insider information related to the transaction, thus not constituting a substantial obstacle to the transaction [8] - Independent financial and legal advisors confirm that the trading activities during the self-inspection period did not involve insider information and do not pose legal obstacles to the transaction [9][10]

Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) is facing potential regulatory penalties due to insider trading allegations against its controlling shareholder Jiang Wei, although the company asserts that this matter will not significantly impact its operations or financials [1][3]. Group 1: Company Structure and Shareholding - Jiang Wei and his spouse You Jie are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [3]. - The regulatory penalty is directed solely at Jiang Wei, and the company clarifies that the issue is unrelated to its business operations [3]. Group 2: Business Overview and Financial Performance - Haohai Biological is a prominent producer of hyaluronic acid in China, operating in four main sectors: aesthetic medicine, ophthalmology, orthopedics, and hemostasis [3]. - In 2024, the revenue breakdown by product category shows that aesthetic medicine accounts for 44.30%, ophthalmic products 31.79%, and orthopedic products 16.92% [3]. - The ophthalmology segment is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [3]. - For the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：环球网 【环球网财经综合报道】9月17日，昊海生科（688366.SH）公告称，公司控股股东、实际控制人之一 蒋伟于今年5月收到中国证监会出具的《立案告知书》，因涉嫌内幕交易被立案调查。昊海生科表示， 该事项仅涉及蒋伟个人，与公司无关，且蒋伟不参与公司日常经营管理，因此不会对公司的日常经营、 业务及财务造成重大影响。公司称，最终行政处罚结果将以中国证监会对蒋伟出具的《行政处罚决定 书》为准，并将持续关注事项进展，及时履行信息披露义务。 （图片来 源：上市公司公告） 公开资料显示，昊海生科业务覆盖玻尿酸、表皮修复基因工程制剂、射频及激光设备四大品类，产品应 用于医疗美容、生活美容及家用美容三大场景。 公司2024年半年度报告显示，受多个产品线主营业务收入减少影响，上半年业绩出现下滑。期内实现营 业收入130,440.28万元，同比下降7.12%；主营业务收入为129,755.17万元，同比减少7.52%。从细分业 务来看，医疗美容与创面护理产品收入57,544.98万元，同比下降9.31%；眼科产品收入36,754.10万元， 降幅达18.61%；骨科产品 ...

Group 1 - Tianpu Co., Ltd. resumed trading on September 18, achieving a 12-day consecutive limit-up, with a cumulative increase of over 200% [1] - The company announced that its stock had been suspended from trading due to significant deviations in short-term price increases compared to the Shanghai Composite Index and the automotive parts industry index [2][3] - Tianpu Co., Ltd. issued a warning to investors about the potential risk of a price drop following the substantial short-term increase [2] Group 2 - In response to market rumors regarding the asset injection by the acquirer Zhonghao Xinying, the company clarified that there are no plans for asset injection related to this acquisition [3] - The company conducted an internal review and found that four insiders had engaged in stock trading during the period from February 14 to August 14, but these transactions did not constitute insider trading [3] - For the first half of 2025, the company reported a revenue of 151 million yuan, a year-on-year decrease of 3.44%, and a net profit attributable to shareholders of 11.298 million yuan, down 16.08% year-on-year [3]

Core Viewpoint - The announcement regarding the administrative penalty against Jiang Wei, a controlling shareholder of Shanghai Haohai Biological Technology Co., Ltd., is significant as it stems from an insider trading investigation by the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Company Overview - Shanghai Haohai Biological Technology Co., Ltd. is a well-known hyaluronic acid producer in China, operating in four major fields: medical aesthetics, ophthalmology, orthopedics, and hemostasis [4]. - The company is recognized as one of the "three giants" in the Chinese hyaluronic acid market, alongside Huaxi Biological and Aimeike [4]. Group 2: Shareholding Structure - Jiang Wei and his spouse, You Jie, are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [4]. Group 3: Financial Performance - In the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [5]. - For 2024, the revenue from the medical aesthetics segment is projected to account for 44.30% of total revenue, while ophthalmology products will contribute 31.79%, and orthopedics will make up 16.92% [4]. - The ophthalmology business is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [4].

9月17日晚间，天普股份（605255）披露交易停牌核查结果，宣布9月18日（星期四）起复牌，且明确公司四名内幕信息知情人在2025年2月14日至2025年8 月14日期间存在买卖公司股票行为。 根据公告，上述四位内幕信息知情人分别为：时任上市公司董事、财务总监陈丹萍配偶储善岳，上市公司职工代表监事唐全良配偶陈燕秋、中昊芯英间接 股东李志奇及其配偶李慧云。其中引人注意的是，李慧云在7月10日至8月6日期间交易动作十分频繁，共有6次买入，2次清仓卖出累计赚取差价5.99万 元。 公司称，四名自然人均已将买卖公司股票所获收益上缴至天普股份。本次控制权变更事项不存在内幕信息提前泄露的情形，上述人员的股票交易行为均发 生在内幕信息形成或知悉之前，上述交易不属于内幕交易。 其一，李慧云的最后一次股票交易发生在8月，与天普股份发布筹划相关事项公告的时间间隔极短，在此背景下，公司所主张的"相关股票交易行为均发生 在内幕信息形成或知悉之前"，其合理性是否能完全成立？ 其二，李志奇身为中昊芯英的间接股东，按常规逻辑本不直接参与公司治理，为何能在全市场五千余家上市公司中，精准选中天普股份进行股票买卖，这 一"巧合"背后是否存在未 ...

【导读】11个交易日连续一字板的天普股份，明日开市起将复牌 对此，天普股份9月17日晚公告称，经公司自查，四名内幕信息知情人在2025年2月14日至2025年8月14 日期间存在买卖公司股票行为。 其中，时任上市公司董事/财务总监（目前已卸任）陈丹萍配偶储善岳、上市公司职工代表监事唐全良 配偶陈燕秋，按规定登记为推定的内幕信息知情人；李志奇作为中昊芯英间接股东，在作为股东代表参 加2025年8月19日（停牌后）中昊芯英股东会时知悉本次交易，其配偶李慧云登记为推定的内幕信息知 情人。 天普股份表示，公司本次控制权变更事项不存在内幕信息提前泄露的情形，上述人员的股票交易行为均 发生在内幕信息形成或知悉之前，上述交易不属于内幕交易。截至2025年9月17日，四名自然人均已将 买卖公司股票所获收益上缴至天普股份。 天普股份还强调，经公司自查，截至公告日，收购方中昊芯英无资产注入计划，中昊芯英自身现有资本 证券化路径亦与本次收购上市公司无关。 11个交易日连续一字板的天普股份，明日起将复牌。 天普股份9月17日晚公告，根据《上海证券交易所上市公司自律监管指引第4号——停复牌》《上海证券 交易所股票上市规则》等相关规定， ...

Core Viewpoint - Tianpu Co., Ltd. (605255) will resume trading on September 18 after being suspended for 11 consecutive trading days due to a stock price surge of 185.29% from August 22 to September 10 [1][2]. Group 1: Trading Resumption - Tianpu Co., Ltd. announced its stock will resume trading on September 18 following a suspension for a price inquiry [1]. - The stock experienced a continuous rise, hitting a price of 76 yuan per share and a market capitalization of 10.2 billion yuan as of September 10 [3]. Group 2: Control Change and Agreements - The company is undergoing a change in control through agreements signed on August 21 and September 15, involving a transfer of shares and capital increase to Zhejiang Tianpu Holdings [1]. - After the completion of the transaction, Yang Gongyifan, the actual controller of TPU chip company Zhonghao Xinying, will become the actual controller of Tianpu Co., Ltd. [1]. Group 3: Insider Trading Allegations - There were market rumors regarding potential insider trading related to the transaction, but Tianpu Co., Ltd. stated that there was no premature disclosure of insider information [1][2]. - Four individuals identified as insiders conducted stock trading before the information was known, and they have returned the profits to the company [2].

Core Viewpoint - Tianpu Co., Ltd. will resume trading on September 18 after being suspended for 11 trading days due to a significant increase in stock price and ongoing acquisition activities [2][4]. Group 1: Stock Performance and Trading Suspension - Tianpu Co., Ltd. experienced a 185.29% increase in stock price from August 22 to September 10, leading to a trading suspension for verification starting September 11 [4]. - The stock price was 76 CNY per share, with a market capitalization of 10.2 billion CNY as of September 10 [7]. Group 2: Acquisition Details - The acquisition involves a transfer of control to Zhonghao Xinying through share transfer and capital increase agreements, with the actual controller being Yang Gong Yifan [4]. - There are no plans for asset injection from Zhonghao Xinying into Tianpu Co., Ltd. as confirmed by the company [6]. Group 3: Insider Trading Allegations - There were rumors of insider information leakage and insider trading related to the acquisition, but Tianpu Co., Ltd. stated that the trading activities of four insiders occurred before the formation or knowledge of the insider information [5][6]. - The company emphasized that the trading actions of the involved individuals do not constitute insider trading, and any profits have been returned to Tianpu Co., Ltd. [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688366 证券简称：昊海生科 公告编号：2025-042 上海昊海生物科技股份有限公司 行政处罚最终结果将以中国证监会对蒋伟先生最终出具的《行政处罚决定书》结论为准。公司将持续关 注上述事项的进展情况，并按照有关法律法规的规定和要求，及时履行信息披露义务，敬请广大投资者 注意投资风险。 特此公告。 上海昊海生物科技股份有限公司董事会 2025年9月17日 收到《行政处罚事先告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）控股股东、实际控制人之一蒋伟先生于2025年5月 收到中国证券监督管理委员会（以下简称"中国证监会"）出具的《立案告知书》（编号：证监立案字 0382025016 号）。因其涉嫌内幕交易，根据《中华人民共和国证券法》《中华人民共和国行政处罚 法》等法律法规，中国证监会决定对其立案。具体内容详见公司于2025年5月8日披露的《上海昊海生物 科技股份有限公司关于控股股东、实际控制人之一 ...